Prostate Cancer Vaccine Development

Multi-antigenic prostate cancer vaccine developed

Published in Cancer Weekly, October 18th, 2005

Researchers describe the large-scale synthesis of peracetylated GM2 glycosylamino acid for preparation of a multi-antigenic prostate cancer vaccine in a recent issue of Bioorganic and Medicinal Chemistry.

"We describe the stereo-controlled, large-scale synthesis of peracetylated GM2 glycosylamino acid. Key features of the synthesis include a newly modified [1 + 3] coupling reaction and an olefin cross-metathesis-hydrogenation sequence," scientists in the United States report.

"The GM2 glycosylamino acid is now ready for incorporation into a hexavalent prostate cancer vaccine construct," said Young Shin Cho and colleagues, Sloan Kettering...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2005-10-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry